Last reviewed · How we verify
adeno-associated virus vector AAV- CNGA3 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
adeno-associated virus vector AAV- CNGA3 (adeno-associated virus vector AAV- CNGA3) — MeiraGTx UK II Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| adeno-associated virus vector AAV- CNGA3 TARGET | adeno-associated virus vector AAV- CNGA3 | MeiraGTx UK II Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- adeno-associated virus vector AAV- CNGA3 CI watch — RSS
- adeno-associated virus vector AAV- CNGA3 CI watch — Atom
- adeno-associated virus vector AAV- CNGA3 CI watch — JSON
- adeno-associated virus vector AAV- CNGA3 alone — RSS
Cite this brief
Drug Landscape (2026). adeno-associated virus vector AAV- CNGA3 — Competitive Intelligence Brief. https://druglandscape.com/ci/adeno-associated-virus-vector-aav-cnga3. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab